How an AI Robot Boosted OCGN's Profit by 7.11%
This AI trading robot from Day Trader ($2K per position): Medium Volatility Stocks for Active Trading (TA&FA), was a top performer in our robot factory over a month, generating 7.11% for OCGN.
OCGN, a medium volatility stock, has been actively traded using both technical analysis (TA) and fundamental analysis (FA) through an AI trading robot from Day Trader that costs $2K per position. This trading robot has been a top performer in the robot factory over a month, generating a 7.11% return for OCGN. However, the recent MACD histogram turning negative on April 25, 2023, is a bearish signal indicating a potential decline in the stock's price going forward.
Tickeron's A.I.dvisor has conducted a historical analysis on 49 instances where the MACD histogram turned negative, revealing that in 47 of the 49 cases, the stock moved lower in the following days. This puts the odds of a downward move at 90%. Therefore, traders and investors should be cautious when trading OCGN, especially given the current bearish signal.
Fundamentally, OCGN's last earnings report on February 28 showed earnings per share of -10 cents, meeting the estimate of -10 cents. This indicates that the company is meeting expectations but not generating a profit yet. With 732.65K shares outstanding, the current market capitalization sits at 163.03M, reflecting the stock's perceived value by the market.
The technical analysis of OCGN's MACD histogram indicates a potential decline in the stock's price going forward, and the fundamental analysis shows that the company is not yet generating a profit. These factors should be taken into consideration by traders and investors when making trading decisions on OCGN.
OCGN's Stochastic Oscillator is remaining in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Show more
Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Inovio Pharmaceuticals (NASDAQ:INO).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.92B. The market cap for tickers in the group ranges from 151 to 584.21B. NONOF holds the highest valuation in this group at 584.21B. The lowest valued company is MYMX at 151.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 19%, and the average quarterly price growth was 20%. PIRS experienced the highest price growth at 127%, while NYMXF experienced the biggest fall at -94%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was 54%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: -10 (-100 ... +100)